Rankings
▼
Calendar
REGN Q4 2024 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$81B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3.8B
+10.3% YoY
Gross Profit
$3.2B
85.1% margin
Operating Income
$990M
26.1% margin
Net Income
$918M
24.2% margin
EPS (Diluted)
$8.06
QoQ Revenue Growth
+1.8%
Cash Flow
Operating Cash Flow
$1.3B
Free Cash Flow
$996M
Stock-Based Comp.
$304M
Balance Sheet
Total Assets
$37.8B
Total Liabilities
$8.4B
Stockholders' Equity
$29.4B
Cash & Equivalents
$2.5B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.8B
$3.4B
+10.3%
Gross Profit
$3.2B
$2.8B
+14.9%
Operating Income
$990M
$1.1B
-5.8%
Net Income
$918M
$1.2B
-20.9%
Revenue Segments
Product
$2.0B
53%
Collaboration Revenue
$1.6B
42%
Product and Service, Other
$179M
5%
← FY 2024
All Quarters
Q1 2025 →